– Company to prioritize industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease, respectively; and to terminate AXO-Lenti-PD license agreement with Oxford Biomedica for Parkinson's disease – Portfolio prioritization allows company to focus resources and extends estimated cash runway into the second half of 2023 – David Nassif, current CFO and General Counsel of Sio, appointed interim CEO following resignation of current CEO and Board Director Dr. Pavan Cheruvu NEW YORK and DURHAM, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today provided a corporate update announcing the prioritization of AXO-AAV-GM1 and AXO-AAV-GM2, its clinical stage AAV gene therapy programs for GM1 and GM2 gangliosidosis (Tay-Sachs/Sandhoff disease).